For Research Use Only. Not for Human Consumption.
Recorded market$46.87Recorded exact-size market estimate: 46.87 USD for one 10 mg container (4.686700 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$56.40Member price$50.76No member savings vs. this market reference
ACTH-derived heptapeptide for neurotrophic research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$5.08/mg
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:29 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Peptara Labs Oct 10, 2026 UTC | One 10 mg container; 150.00 USD | $15.00/mg | powder; publicly listed Bacteriostatic water included at no separately stated price; no email discount used. Price observation; no COA authentication is implied by inclusion. |
| SF Bay Area Peptides Oct 10, 2026 UTC | One 10 mg container; 39.95 USD | $4.00/mg | powder; publicly listed Entry overlay; visible public price and USD offer accessible without terms acceptance. Price observation; no COA authentication is implied by inclusion. |
| Pepta Labs Oct 10, 2026 UTC | One 10 mg container; 27.74 USD | $2.77/mg | powder; publicly listed Price observation; no COA authentication is implied by inclusion. |
| Beach Bio Research Oct 10, 2026 UTC | One 10 mg container; 20.00 USD | $2.00/mg | powder; publicly listed Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 10, 2026 UTC | One 10 mg container; 24.99 USD | $2.50/mg | powder; publicly listed Price observation; no COA authentication is implied by inclusion. |
| BioInfinity Oct 10, 2026 UTC | One 10 mg container; 36.00 USD | $3.60/mg | powder; publicly listed Price observation; no COA authentication is implied by inclusion. |
| Pepsynth Labs Oct 10, 2026 UTC | One 10 mg container; 30.00 USD | $3.00/mg | powder; publicly listed Price observation; no COA authentication is implied by inclusion. |
| VECTOR Peptides Oct 10, 2026 UTC | One 10 mg container; 34.99 USD | $3.50/mg | powder; publicly listed VECTOR domain redirects to American Biotech; counted once under final domain. Price observation; no COA authentication is implied by inclusion. |
| BulkGLP Oct 11, 2026 UTC | One 10 mg container; 55.00 USD | $5.50/mg | lyophilized powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Santa Cruz Peptides Oct 11, 2026 UTC | One 10 mg container; 50.00 USD | $5.00/mg | lyophilized powder; In stock Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Semax – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/semax-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/semax-10-mg/
A heptapeptide derived from an ACTH fragment, studied in laboratory models of neurotrophic signaling and cognitive function.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Semax is an ACTH-related synthetic peptide investigated in neurological settings. Human reports reviewed here concern stroke care and rehabilitation, not established enhancement of cognition in healthy people.
The clinical source describes Semax as a synthetic derivative of ACTH 4-10. Modified products sold with additional chemical prefixes need their own identity and evidence.
An ACTH-derived name does not mean a product reproduces all actions of full-length ACTH or that any related peptide has the same effects.
There are human clinical reports, so calling the entire literature animal-only would be inaccurate. Their design and setting still limit the conclusions. The two reviewed abstracts study Semax alongside other care in people who have had ischemic stroke; neither is a blinded healthy-volunteer nootropic trial.
| Study and design | Finding | What it does not establish |
|---|---|---|
| [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].
Comparison of 30 treated acute-stroke patients with 80 conventionally treated controls Reading scope: PubMed bibliographic record and abstract |
The authors reported faster improvement in selected neurological measures with Semax added to intensive care. | The abstract does not describe randomized allocation or masking; concurrent care and differing groups limit causal interpretation. |
| [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].
Study of 110 post-stroke patients grouped by rehabilitation timing and Semax exposure Reading scope: PubMed bibliographic record and abstract |
The authors reported changes in circulating BDNF and functional scores, with associations also related to rehabilitation timing. | The abstract does not establish a randomized placebo-controlled design; a biomarker correlation does not prove how recovery occurred. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Circulating BDNF is not a direct measurement of new brain cells or improved memory. Its change should not be converted into a clinical claim beyond the outcomes actually measured.
Recovery after stroke depends on many factors. Baseline deficits, rehabilitation and concurrent treatment need to be accounted for before assigning the improvement to one added agent.
Evidence for a narrowly defined neurological population cannot establish everyday cognitive enhancement in people without that condition.
The two abstracts do not provide a comprehensive adverse-event assessment or evidence for long-term use in healthy adults. Stroke is an urgent medical condition; these research summaries cannot guide self-treatment or replace acute stroke care.
The published stroke exposures belong to those clinical protocols. Do not reuse them as a personal nootropic regimen or derive a schedule from animal gene-expression experiments.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Specify ordinary Semax versus any acetylated or amidated derivative and require an identity method supporting that distinction. A report for one modified form cannot authenticate another.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Yes, including the stroke reports summarized here. That does not remove their design limitations or establish all promoted uses.
No. A blood biomarker, functional recovery after stroke and memory performance are different endpoints.
A chemical modification can change the material. Its exact structure and exposure need to match before results can be transferred.
This companion to the Semax research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
The published stroke exposures belong to those clinical protocols. Do not reuse them as a personal nootropic regimen or derive a schedule from animal gene-expression experiments.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.